Free Trial
LON:IMM

ImmuPharma (IMM) Share Price, News & Analysis

ImmuPharma logo
GBX 3.44 -0.06 (-1.74%)
As of 12:31 PM Eastern

About ImmuPharma Stock (LON:IMM)

Key Stats

Today's Range
3.16
3.56
50-Day Range
2.15
4
52-Week Range
0.85
7.40
Volume
4.62 million shs
Average Volume
9.59 million shs
Market Capitalization
£14.64 million
P/E Ratio
N/A
Dividend Yield
0.77%
Price Target
N/A
Consensus Rating
N/A

Company Overview

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

Receive IMM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmuPharma and its competitors with MarketBeat's FREE daily newsletter.

IMM Stock News Headlines

Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
ImmuPharma PLC (25I.MU)
ImmuPharma Targets Global Partnerships at Key Biotech Events
See More Headlines

IMM Stock Analysis - Frequently Asked Questions

ImmuPharma's stock was trading at GBX 1.18 at the start of the year. Since then, IMM shares have increased by 192.4% and is now trading at GBX 3.44.
View the best growth stocks for 2025 here
.

ImmuPharma plc (LON:IMM) posted its quarterly earnings data on Wednesday, September, 30th. The company reported ($1.69) EPS for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative trailing twelve-month return on equity of 131.41%.

Shares of IMM stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

Based on aggregate information from My MarketBeat watchlists, some other companies that ImmuPharma investors own include Castleton Technology (CTP), 4D pharma (DDDD), MOTIF BIO PLC/S (MTFB), Nikola (NKLA), Thor Energy (THR), Aminex (AEX) and GSK (GSK).

Company Calendar

Last Earnings
9/30/2020
Today
5/02/2025

Industry, Sector and Symbol

Stock Exchange
LON
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
LON:IMM
CIK
N/A
Fax
N/A
Employees
13
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
£-2,509,806.21
Net Margins
3,519.56%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£-71,310.29
Cash Flow
GBX 0.17 per share
Price / Cash Flow
20.50
Book Value
GBX 0.65 per share
Price / Book
5.34

Miscellaneous

Free Float
N/A
Market Cap
£14.64 million
Optionable
Not Optionable
Beta
1.53
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (LON:IMM) was last updated on 5/2/2025 by MarketBeat.com Staff
From Our Partners